Physician profile
Richard Mallo
NPI 1588699490
$1,110.98
in general payments reported to CMS, 2019-2025
20 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.09 · 2021: $179 · 2022: $81.56 · 2023: $315 · 2024: $225 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $191.85 | 2023 | Freestyle Libre 3 |
| Biotronik INC. | $163.49 | 2021-2023 | Biomonitor |
| Astrazeneca Pharmaceuticals LP | $152.15 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $101.96 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $88.80 | 2023-2025 | Rexulti |
| Abbvie INC. | $65.36 | 2023-2024 | |
| Lilly USA, LLC | $63.09 | 2022-2025 | Mounjaro, Zepbound |
| Acadia Pharmaceuticals INC | $36.79 | 2021-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $31.57 | 2025 | |
| Astellas Pharma US INC | $29.59 | 2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $28.63 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $27.95 | 2025 | |
| Avanir Pharmaceuticals, INC. | $22.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.31 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.11 | 2019 | |
| Smith+Nephew, INC. | $15.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.60 | 2025 | |
| Phadia US INC. | $13.44 | 2024 | Immunocap |
| Biowound Solutions, INC. | $9.57 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.